Zidovudine (AZT)

The first NRTI (Nucleoside Reverse Transcriptase Inhibitor) approved for HIV. It blocks the virus's ability to replicate its DNA.

Dosage by Body Weight

For neonates (prevention): 4 mg/kg twice daily for 4–6 weeks. For treatment: weight-band based.

Weight-based dosage tracking table for Zidovudine (AZT), including body weight, dose, frequency, and tracking notes.
Body Weight	Dose	Frequency	Tracking Notes
4-9 kg	60 mg (6 ml syrup)	Twice daily	Monitor for anemia (low red blood cell count).
10-14 kg	100 mg	Twice daily	Commonly part of a three-drug regimen.

SyrupCapsuleInjection

Treatment of HIV-1 infection and prevention of mother-to-child transmission.

Zidovudine (AZT) is listed as a generic drug name. Common branded medicines that may contain the same active ingredient include:

Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.

CAUTION

Zidovudine (AZT): Alcohol may worsen dizziness, nausea, dehydration, or liver strain during antiviral treatment. Avoid or limit alcohol.

SAFE IF PRESCRIBED

Zidovudine (AZT): Use during pregnancy only when prescribed; treatment may be important for maternal infection control or prevention of transmission.

SAFE IF PRESCRIBED

Zidovudine (AZT): Breastfeeding advice depends on the infection and treatment regimen. Use only with healthcare provider guidance.

CAUTION

Zidovudine (AZT): May cause dizziness, fatigue, sleep disturbance, or headache. Avoid driving if alertness is affected.

CAUTION

Zidovudine (AZT): Some antivirals can affect liver function or require monitoring in hepatitis, HIV, or severe illness.

CAUTION

Zidovudine (AZT): Several antivirals are cleared by the kidneys and may need dose adjustment or hydration. Consult your healthcare provider.